[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2016010169A - Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina. - Google Patents

Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Info

Publication number
MX2016010169A
MX2016010169A MX2016010169A MX2016010169A MX2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A MX 2016010169 A MX2016010169 A MX 2016010169A
Authority
MX
Mexico
Prior art keywords
cgrp
active compounds
tablet formulation
api
formula
Prior art date
Application number
MX2016010169A
Other languages
English (en)
Inventor
Xu Wei
NOFSINGER Rebecca
LUPTON Lisa
ann johnson Mary
Resende ALLAIN Leonardo
Mark Eickhoff W
B Ikeda Craig
D Brown Chad
J Jr Flanagan Francis
Marota Melanie
B Patel Paresh
XI Hanmi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53778348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016010169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016010169A publication Critical patent/MX2016010169A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a composiciones que comprenden un material extrudido o solución sólida de un compuesto, o una sal del mismo, de fórmula I (API): fórmula I, (ver Fórmula) en donde ``Ra´´ es independientemente H o -F, en una matriz de polímero soluble en agua, la cual comprende adicionalmente un sistema de desintegración que permite que una tableta obtenida del mismo se desintegre rápidamente en el ambiente en el cual el API será liberado.
MX2016010169A 2014-02-05 2015-01-30 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina. MX2016010169A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936019P 2014-02-05 2014-02-05
US201462087366P 2014-12-04 2014-12-04
PCT/US2015/013672 WO2015119848A1 (en) 2014-02-05 2015-01-30 Tablet formulation for cgrp-active compounds

Publications (1)

Publication Number Publication Date
MX2016010169A true MX2016010169A (es) 2016-10-07

Family

ID=53778348

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010169A MX2016010169A (es) 2014-02-05 2015-01-30 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
MX2021006790A MX2021006790A (es) 2014-02-05 2016-08-04 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006790A MX2021006790A (es) 2014-02-05 2016-08-04 Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.

Country Status (13)

Country Link
US (4) US10117836B2 (es)
EP (1) EP3102564A4 (es)
JP (2) JP6491669B2 (es)
KR (3) KR102448369B1 (es)
CN (2) CN105960397B (es)
AU (4) AU2015214502B2 (es)
CA (1) CA2937315A1 (es)
HK (1) HK1232218A1 (es)
IL (1) IL246828B (es)
MX (2) MX2016010169A (es)
RU (2) RU2019123406A (es)
SA (1) SA516371613B1 (es)
WO (1) WO2015119848A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
MX2016010169A (es) 2014-02-05 2016-10-07 Merck Sharp & Dohme Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
CN105126111A (zh) * 2015-09-30 2015-12-09 清华大学 提高索拉非尼生物利用度的制剂
FI3601277T3 (fi) * 2017-03-30 2024-01-09 Merck Patent Gmbh Farmaseuttinen formulaatio
WO2019191008A1 (en) * 2018-03-25 2019-10-03 Biohaven Pharmaceutical Holding Company Ltd. Rimegepant for cgrp related disorders
RU2755571C1 (ru) * 2020-06-09 2021-09-17 Сергей Геннадьевич Каплунов Способ изготовления гравюры на металле
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
MX2023007575A (es) 2020-12-22 2023-09-21 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US20040076668A1 (en) * 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
ATE535514T1 (de) 2003-03-14 2011-12-15 Merck Sharp & Dohme Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
WO2004087649A2 (en) 2003-03-14 2004-10-14 Merck & Co., Inc. Benodiazepine spirohydantoin cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
DE602005020656D1 (de) 2004-09-13 2010-05-27 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
DE102004063755A1 (de) 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
ATE537170T1 (de) 2005-03-14 2011-12-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
WO2007092642A2 (en) * 2006-02-09 2007-08-16 Merck & Co., Inc. Polymer formulations of cetp inhibitors
WO2007133491A1 (en) 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
WO2008153849A1 (en) 2007-06-05 2008-12-18 Merck & Co., Inc. Carboxamide heterocyclic cgrp receptor antagonists
MX2010003849A (es) 2007-10-18 2010-04-27 Boehringer Ingelheim Int Antagonistas de cgrp.
US20120149698A1 (en) 2007-11-22 2012-06-14 Boehringer Ingelheim International Gmbh Nouvel compounds
CA2722536A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
PE20091778A1 (es) 2008-04-15 2009-11-13 Schering Corp Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden
HUE033494T2 (en) * 2009-03-31 2017-12-28 Ligand Pharm Inc Biphenylsulfonamide Endothelin and Angiotensin II Receptor Antagonist for Glomerulosclerosis
WO2010139717A1 (de) 2009-06-05 2010-12-09 Boehringer Ingelheim International Gmbh Neue verbindungen
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP2013542261A (ja) 2010-11-12 2013-11-21 メルク・シャープ・アンド・ドーム・コーポレーション ピペリジノンカルボキサミドインダンｃｇｒｐ受容体アンタゴニスト
TWI522355B (zh) 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2013066360A1 (en) 2010-12-22 2013-05-10 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
EP2654421B1 (en) 2010-12-22 2016-10-19 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide as cgrp receptor antagonists
MX2013010306A (es) * 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
EP2685826B1 (en) 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9109209B2 (en) 2011-09-08 2015-08-18 Codexis, Inc. Biocatalysts and methods for the synthesis of substituted lactams
CA3114454C (en) 2011-10-14 2022-11-29 Array Biopharma Inc. A solid dispersion of n4-(4-([1,2,4]triazolo[1,5-.alpha.]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
WO2013138413A1 (en) 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
JP2015514803A (ja) 2012-04-25 2015-05-21 イノーバス ファーマシューティカルズ インコーポレイテッド 増感組成物および使用方法
EP2846799B1 (en) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
US9227973B2 (en) 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Pyridine CGRP receptor antagonists
WO2013169574A2 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
TWI661825B (zh) 2013-03-15 2019-06-11 托尼克製藥有限公司 環苯扎林鹽酸鹽及阿密替林鹽酸鹽之共晶調配物
MX2016003394A (es) 2013-09-16 2016-10-28 Merck Sharp & Dohme Formulaciones para antagonistas del receptor del cgrp.
MX2016010169A (es) 2014-02-05 2016-10-07 Merck Sharp & Dohme Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
EP3102188A4 (en) 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
CA2949480A1 (en) 2014-02-24 2015-08-27 Urigen Pharmaceuticals, Inc. Compositions of pentosan polysulfate salts for oral administration and methods of use
CN106794185A (zh) 2014-08-22 2017-05-31 克洛维斯肿瘤有限公司 Rucaparib的高剂量强度片剂
TW201642853A (zh) 2015-01-23 2016-12-16 歌林達有限公司 用於治療肝功能之損傷及／或腎功能之損傷個體疼痛之西博帕多（Ｃｅｂｒａｎｏｐａｄｏｌ）
AU2016325738A1 (en) 2015-09-24 2018-04-12 Teva Pharmaceuticals International Gmbh Preventing, treating, and reducing (persistent) post-traumatic headache
US20180092899A1 (en) 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
WO2018160896A1 (en) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190135927A1 (en) 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
US20190374518A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374520A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
EP3956025A1 (en) 2019-04-18 2022-02-23 Allergan Sales, LLC Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
EP4034156A4 (en) 2019-09-25 2024-01-24 Allergan Pharmaceuticals International Limited COMBINATION THERAPY WITH CGRP ANTAGONISTS
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
MX2023007575A (es) 2020-12-22 2023-09-21 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Also Published As

Publication number Publication date
KR20230107902A (ko) 2023-07-18
AU2015214502B2 (en) 2019-06-06
WO2015119848A1 (en) 2015-08-13
CN112022818A (zh) 2020-12-04
US10117836B2 (en) 2018-11-06
EP3102564A4 (en) 2017-10-18
IL246828B (en) 2019-05-30
JP2017505306A (ja) 2017-02-16
MX2021006790A (es) 2021-07-15
US20190209478A1 (en) 2019-07-11
JP6666490B2 (ja) 2020-03-13
CN105960397A (zh) 2016-09-21
RU2019123406A (ru) 2019-10-03
AU2019226239B2 (en) 2021-07-08
BR112016017999A2 (es) 2017-08-08
EP3102564A1 (en) 2016-12-14
US20230248655A1 (en) 2023-08-10
JP6491669B2 (ja) 2019-03-27
AU2019226239A1 (en) 2019-09-26
IL246828A0 (en) 2016-08-31
US20160346214A1 (en) 2016-12-01
KR20160113296A (ko) 2016-09-28
CA2937315A1 (en) 2015-08-13
HK1232218A1 (zh) 2018-01-05
KR102448369B1 (ko) 2022-09-28
US11925709B2 (en) 2024-03-12
CN105960397B (zh) 2020-09-04
JP2019108366A (ja) 2019-07-04
BR112016017999A8 (pt) 2023-04-11
AU2023258317A1 (en) 2023-11-16
RU2696578C1 (ru) 2019-08-05
AU2021245229A1 (en) 2021-11-04
SA516371613B1 (ar) 2021-06-19
KR20220136460A (ko) 2022-10-07
US20210085612A1 (en) 2021-03-25
AU2015214502A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
MX2021006790A (es) Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2017014035A (es) Formas solidas novedosas.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12016501807A1 (en) Novel compounds
PH12016501462A1 (en) Neprilysin inhibitors
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
EP4327880A3 (en) Solid state form of ribociclib succinate
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2019004294A (es) Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogenicos indeseados.
MX2017007377A (es) Compuestos organicos.
PH12018501709A1 (en) Naphthridinedione derivatives
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MX371158B (es) Compuestos inhibidores de pde2.
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2016011572A (es) Composiciones antimicrobianas de acido organico.
MX2017016108A (es) Capsulas de capecitabina de liberacion prolongada.
MX2016011310A (es) Agente para el control de endoparasitos.
WO2016026014A8 (pt) Derivado de ácido perílico, processo para a preparação de um derivado de ácido perílico, composição farmacêutica, uso de um derivado de ácido perílico e método de tratamento de câncer